NCT06585969 2026-02-12
DISCORDANT
Danish Breast Cancer Cooperative Group
Phase 3 Withdrawn
Clinical Trials
9 trialsNCT04118036 2025-08-11
Abemaciclib + Pembrolizumab In Glioblastoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT04316169 2022-12-23
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
Medical College of Wisconsin
Phase 1 Withdrawn
NCT04585724 2021-10-18
Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases
Emory University
Phase 1 Withdrawn
NCT03846583 2020-10-23
Tucatinib + Abemaciclib + Herceptin for HER2+ MBC
Dana-Farber Cancer Institute
Phase 1 Withdrawn
NCT04220892 2020-07-31
Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma
Saint John's Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT04088032 2020-07-16
Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer
Stony Brook University
Phase EARLY_PHASE1 Withdrawn
NCT04272645 2020-07-15
Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn
NCT03988114 2019-09-06
proMONARCH
Eli Lilly and Company
Phase 4 Withdrawn